The HSR clearance significantly de-risks the merger timeline. The next catalyst is the July 8 stockholder vote; monitor for any dissident opposition or competing bids. If approved, the stock should converge toward the merger consideration.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Jun 17 $3.17entry
- T+1 · 5mo ago −0.63%α −1.41% · $3.15
- T+5 · 5mo ago −0.63%α +0.41% · $3.15
- T+20 · due 4mo ago Pending
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics disclosed that the Hart-Scott-Rodino waiting period for its pending merger with an affiliate of ArchiMed SAS expired on June 15, 2026, removing a key regulatory condition. The special stockholder meeting to vote on the merger is scheduled for July 8, 2026, and the deal remains subject to stockholder approval and other customary closing conditions.
Key Financial Metrics
Key Facts
- HSR waiting period for the ArchiMed merger expired on June 15, 2026.
- Special stockholder meeting to vote on the merger is set for July 8, 2026.
- Merger agreement was entered into on May 1, 2026, with Essence Parent Inc. (ArchiMed affiliate).
- Closing remains subject to stockholder adoption and other customary conditions.
Financial Impact
Not specified
Risk Factors
- Stockholder approval is not guaranteed; failure to adopt would terminate the deal.
- Other closing conditions (e.g., no material adverse change) could still block completion.
- Potential litigation or regulatory delays beyond HSR.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-074562 |
| Document: 0001104659-26-074562-index-headers.html | 0001104659-26-074562 |
| Document: 0001104659-26-074562-index.html | 0001104659-26-074562 |
| Document: 0001104659-26-074562.txt | 0001104659-26-074562 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Viewing Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers